Preeclampsia is a progressive and pregnancy-specific disorder and it affects multiorgan systems. Although the pathophysiology of preeclampsia is still unknown, it involves both maternal and fetal/placental factors. Endothelial cell damage and impaired endothelial cell function play an important role in the development of preeclampsia. Adipokines have role in many pathophysiological processes in the body. Subfatin is a newly discovered adipokine, if dysfunctional may cause endothelial damage. This study investigated whether subfatin levels can be used as a predictive marker for possible pathophysiology. This study was designed as prospective case-control study. Fifty-six pregnant women who had delivered between gestational age of 37th and 41th weeks with singleton pregnancies in a tertiary reference hospital were included. Pregnant women with a diagnosis of preeclampsia were defined as the case group and normotensive pregnants without a diagnosis of preeclampsia were defined as the control group. There was no statistically significant difference in terms of age, BMI, gravidity and parity between the groups. Mean systolic and diastolic blood pressures were observed higher in case group than control group. Subfatin level of control group was found higher than case group and this difference was statistically significant. Subfatin level = 49.32 ng/mL with 78.6% sensitivity and 71.4% specificity was found significant for case group. Subfatin may have a role in endothelial dysfunction and take part in pathophysiology of preeclampsia. According to this study we suggest that as a newly diagnosed adipokine, subfatin may be helpful in predicting preeclampsia development in pregnant women. [ABSTRACT FROM AUTHOR]